Goldenseal for Health & Longevity

Created on 11/17/2026 – Quick Reference based on Evidence Review created using AI4L + evidence-mcp / Opus 5.5 – Audit

Goldenseal, a North American root herb sold as a dietary supplement and traditionally used for infections and digestive complaints, has almost no human outcome research. Suggested blood sugar and cholesterol benefits rest mostly on studies of its main compound, berberine, taken in much larger amounts. Repeated human studies show it slows enzymes that clear many prescription drugs, so for people taking regular medications the drug-interaction picture dominates the balance. (Full Review)

Protocol

Trial regimen, capsules
1 g three times daily
For 5–6 days; other trials used 1,140 mg twice daily or 3,210 mg daily for 14 days
Short-term upper exposure
About 3 g daily
For short periods without serious harmful effects
Best time of day
About 8 am, 12 pm and 4 pm
Dose spacing used in a drug-interaction trial; split dosing two to three times daily is standard
Time to effect
HbA1c change
28 days
With metformin, without a control group; no symptom-benefit timeline has been established
Drug-enzyme inhibition
14 days
Shown as raised midazolam levels; activity returns only as new enzyme is made

Benefits

Contraindications
  • Pregnant women
  • Breastfeeding women, newborns and infants
  • Organ-transplant recipients on cyclosporine or tacrolimus
  • People on narrow-margin CYP3A4 or CYP2D6 drugs without monitoring (flecainide, carbamazepine)
Key Interactions
  • CYP3A4 substrates (drugs CYP3A4 clears: midazolam, triazolam, simvastatin)
  • CYP2D6 substrates (drugs CYP2D6 clears: dextromethorphan, metoprolol, codeine)
  • Metformin
  • Cyclosporine
  • Over-the-counter CYP2D6 or CYP3A4 substrates (diphenhydramine, loratadine)
  • Warfarin
Theoretical (inferred from mechanism)
  • Other glucose-lowering drugs (insulin, glipizide)
  • Berberine-containing supplements (berberine, Oregon grape)
  • Glucose-lowering supplements (cinnamon, chromium)
  • Grapefruit juice and ultraviolet exposure

Risk & Side Effects

  • High: Inhibition of drug-clearing enzymes CYP3A4 and CYP2D6
  • Medium: Reduced metformin exposure
  • Low: Gastrointestinal discomfort, phototoxic skin reaction, hypernatremia
  • Speculative: Liver tumors in rodents, newborn bilirubin brain injury

Monitoring

Marker Target Why
HbA1c 4.0–5.6% Glucose lowering
Fasting glucose 70–99 mg/dL Glucose lowering; low-glucose safety check with diabetes drugs
ALT 7–56 U/L Liver injury safety check
Cyclosporine or tacrolimus trough No established target; transplant team's individual target range Drug-level safety check

Cadence: Baseline medication review, ALT, and fasting glucose and HbA1c in diabetes or prediabetes (plus trough level in transplant recipients); fasting glucose weekly for the first 4 weeks in metformin users; trough levels 1–2 weeks after starting or stopping; ALT at 4–8 weeks if use continues beyond a month; HbA1c at 3 months.

Qualitative Assessment

  • Digestive comfort (cramping, bloating, bowel changes)
  • Skin reactions on sun-exposed areas
  • New drowsiness, dizziness or side effects from existing medications
  • Relief of the symptom for which goldenseal was started (e.g., digestive discomfort)
  • Energy levels and general well-being